Dermata Therapeutics
DRMA
6 hedge funds and large institutions have $29.8K invested in Dermata Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.05% less ownership
Funds ownership: 0.06% → 0.01% (-0.05%)
84% less capital invested
Capital invested by funds: $185K → $29.8K (-$155K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$9.15K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$8.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$133K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$16.5K |
| 3 |
VF
Virtu Financial
New York
|
-$8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$344 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TSS
1
Two Sigma Securities
New York
| $8.2K | +$9.15K | +133 | New |
|
|
2
Citadel Advisors
Miami,
Florida
| $7.03K | +$8.05K | +117 | New |
|
|
3
Acadian Asset Management
Boston,
Massachusetts
| $7K | -$16.5K | -240 | -65% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $4.92K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $2.36K | -$344 | -5 | -12% |
|
6
Wells Fargo
San Francisco,
California
| $289 | – | – | – |
|
7
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $6 | – | – | – |
|
|
AC
8
Armistice Capital
New York
| – | -$133K | -1,453 | Closed |
|
|
VF
9
Virtu Financial
New York
| – | -$8K | -90 | Closed |
|
DRMA Hedge Fund Activity: Q1 2024 in Review
6 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q1 2024, worth a combined $29.8K — down 84% from $185K a quarter earlier.
Fund positioning in DRMA was balanced in Q1 2024: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $9.15K. The largest seller was Armistice Capital, exiting entirely with an estimated $133K sold.
- 6 institutional investors held Dermata Therapeutics (DRMA) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $29.8K of Dermata Therapeutics stock for Q1 2024, down 84% quarter-over-quarter.
- 2 funds opened new Dermata Therapeutics positions in Q1 2024 and 2 closed out, a net change of 0 holders.
- The largest Dermata Therapeutics buyer in Q1 2024 was Two Sigma Securities, an estimated $9.15K added.
- The largest Dermata Therapeutics seller in Q1 2024 was Armistice Capital, an estimated $133K sold.
Based on aggregated 13F filings for Q1 2024.